Package leaflet: Information for the patient

Solifenacin TAD 5 mg
film-coated tablets
Solifenacin TAD 10 mg
film-coated tablets

solifenacin succinate

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Solifenacin TAD is and what it is used for

The active substance of Solifenacin TAD belongs to the group of anticholinergics. These medicines are used to reduce the activity of an overactive bladder. This enables you to wait longer before having to go to the bathroom and increases the amount of urine that can be held by your bladder.

Solifenacin TAD is used to treat the symptoms of a condition called overactive bladder. These symptoms include: having a strong, sudden urge to urinate without prior warning, having to urinate frequently or wetting yourself because you could not get to the bathroom in time.

2. What you need to know before you take Solifenacin TAD

Do not take Solifenacin TAD
- if you are allergic to solifenacin or any of the other ingredients of this medicine (listed in section 6),
- if you have an inability to pass water or to empty your bladder completely (urinary retention),
- if you have a severe stomach or bowel condition (including toxic megacolon, a complication associated with ulcerative colitis),
- if you suffer from the muscle disease called myasthenia gravis, which can cause an extreme weakness of certain muscles,
- if you suffer from increased pressure in the eyes, with gradual loss of eye sight (glaucoma),
- if you are undergoing kidney dialysis,
- if you have severe liver disease,
- if you suffer from severe kidney disease or moderate liver disease AND at the same time are being treated with medicines that may decrease the removal of Solifenacin TAD from the body (for example, ketoconazole). Your doctor or pharmacist will have informed you if this is the case.

Inform your doctor if you have or ever had any of the above mentioned conditions before treatment with Solifenacin TAD starts.

Warnings and precautions
Talk to your doctor or pharmacist before taking Solifenacin TAD.
- If you have trouble emptying your bladder (= bladder obstruction) or have difficulty in passing urine (e.g. a thin urine flow). Risk of accumulation of urine in the bladder (urinary retention) is much higher.
- If you have some obstruction of the digestive system (constipation).
- If you are at risk of your digestive system slowing down (stomach and bowel movements). Your doctor will have informed you if this is the case.
- If you suffer from severe kidney disease.
- If you have moderate liver disease.
- If you have a stomach tear (hiatus hernia) or heartburn.
- If you have a nervous disorder (autonomic neuropathy).

Inform your doctor if you have or ever had any of the above mentioned conditions before treatment with Solifenacin TAD starts.

Before starting Solifenacin TAD, your doctor will assess whether there are other causes for your need to pass urine frequently (for example heart failure (insufficient pumping power of the heart) or kidney disease). If you have a urinary tract infection, your doctor will prescribe you an antibiotic (a treatment against particular bacterial infections).

Children and adolescents
Solifenacin TAD is not to be used in children or adolescents under 18 years.

Other medicines and Solifenacin TAD
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

It is especially important to inform your doctor if you are taking:
- other anticholinergic medicines, effects and side effects of both medications can be enhanced.
- cholinergics as they can reduce the effect of Solifenacin TAD.
- medicines, like metoclopramide and cisapride, which make the digestive system work faster. Solifenacin TAD can reduce their effect.
- medicines, like ketoconazole, ritonavir, nelfinavir, intraconazole, verapamil and diltiazem, which decrease the rate at which Solifenacin TAD is broken down by the body.
- medicines like rifampicin, phenytoin and carbamazepine, as they may increase the rate at which Solifenacin TAD is broken down by the body.
- medicines such as bisphosphonates, that can cause or exacerbate inflammation of the gullet (oesophagitis).

Solifenacin TAD with food and drink
Solifenacin TAD can be taken with or without food, depending on your preference.

Pregnancy and breast-feeding
You should not use Solifenacin TAD if you are pregnant unless clearly necessary. Do not use Solifenacin TAD if you are breast-feeding as solifenacin may get into your breast milk.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
Solifenacin TAD may cause blurred vision and sometimes sleepiness or tiredness. If you suffer from any of these side effects, do not drive or operate machinery.

Solifenacin TAD contains lactose
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Solifenacin TAD

Instructions for proper use
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

You should swallow the whole tablet with some liquid. It can be taken with or without food, according to your preference. Do not crush the tablets.

The recommended dose is 5 mg per day, unless your doctor told you to take 10 mg per day.

If you take more Solifenacin TAD than you should
If you have taken too much Solifenacin TAD or if a child has accidentally taken Solifenacin TAD, contact your doctor or pharmacist immediately.

Symptoms of overdose may include: headache, dry mouth, dizziness, drowsiness and blurred vision, perceiving things that are not there (hallucinations), over-excitability, seizures (convulsions), difficulty breathing, elevated heart rate (tachycardia), accumulation of urine in the bladder (urinary retention) and dilated pupils (mydriasis).

If you forget to take Solifenacin TAD
If you forget to take a dose at the usual time, take it as soon as you remember, unless it is time to take your next dose. Never take more than one dose per day. If you are in doubt, always consult your doctor or pharmacist.

If you stop taking Solifenacin TAD
If you stop taking Solifenacin TAD, your symptoms of overactive bladder may return or worsen. Always consult your doctor if you consider stopping treatment.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Stop taking Solifenacin TAD and seek medical help immediately if you notice any of the following side effects:
- allergic attack, or a severe skin reaction (e.g. blistering and peeling of the skin);
- angioedema (skin allergy that results in the swelling that occurs in the tissue just below the surface of the skin) with airway obstruction (difficulty in breathing) has been reported in some patients on solifenacin succinate(Solifenacin TAD).

Solifenacin TAD may cause the following other side effects:

Very common (may affect more than 1 in 10 people):
- dry mouth.

Common (may affect up to 1 in 10 people):
- blurred vision,
- constipation, nausea, indigestion with symptoms such as a abdominal fullness, abdominal pain, burping, nausea, and heartburn (dyspepsia), stomach discomfort.

Uncommon (may affect up to 1 in 100 people):
- urinary tract infection, bladder infection,
- sleepiness,
- impaired sense of taste (dysgeusia),
- dry (irritated) eyes,
- dry nasal passages,
- reflux disease (gastro-oesophageal reflux), dry throat,
- dry skin,
- difficulty in passing urine,
- tiredness, accumulation of fluid in the lower legs (oedema).

Rare (may affect up to 1 in 1,000 people):
- lodging of a large amount of hardened stool in the large intestine (faecal impaction),
- build up of urine in the bladder due to inability to empty the bladder (urinary retention),
- dizziness, headache,
- vomiting
- itching, rash.

Very rare (may affect up to 1 in 10,000 people):
- hallucinations, confusion,
- allergic rash.

- BlackU
- BlackU (60%)

KRKA
Article name.: PL. SOLIFENACIN TAD fct IE
Prepared by: A. Mohorič
Date: 02.11.2020

Not known (frequency cannot be estimated from the available data)
- decreased appetite, high levels of blood potassium which can cause abnormal heart rhythm,
- increased pressure in the eyes,
- changes in the electrical activity of the heart (ECG), irregular heartbeat, feeling your heartbeat, faster heart beat
- voice disorder,
- liver disorder,
- muscle weakness,
- renal disorder.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via
HPRA Pharmacovigilance
Website: www.hpra.ie.
By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Solifenacin TAD

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Tablet container after first opening
Do not store above 25°C.

Shelf life after the first opening is 12 months.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Solifenacin TAD contains
- The active substance is solifenacin succinate.
  Solifenacin TAD 5 mg film-coated tablets: Each 5 mg film-coated tablet contains 5 mg solifenacin succinate corresponding to 3.8 mg solifenacin.
  Solifenacin TAD 10 mg film-coated tablets: Each 10 mg film-coated tablet contains 10 mg solifenacin succinate corresponding to 7.5 mg solifenacin.
- The other ingredients are:
  tablet core: lactose monohydrate, povidone and magnesium stearate. See section 2 “Solifenacin TAD contains lactose”.
  film coating: hypromellose, talc, titanium dioxide (E171), triacetin and red iron oxide (E172) (only in 10 mg tablets).

What Solifenacin TAD looks like and contents of the pack
Solifenacin TAD 5 mg film-coated tablets
White to brown white, round, slightly convex film-coated tablets with beveled edges. Tablet diameter: 7.5 mm.
Solifenacin TAD 10 mg film-coated tablets
Pinkish white, round, slightly convex film-coated tablets with beveled edges. Tablet diameter: 7.5 mm.

Boxes of 10, 30, 50, 60, 90 and 100 film-coated tablets in blisters are available.
Boxes of 250 film-coated tablets in tablet containers are available.

Not all pack sizes may be marketed.

Marketing Authorisation Holder
TAD Pharma GmbH, Heinz-Lohmann-Straße 5,
27472 Cuxhaven, Germany

Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6,
8501 Novo mesto, Slovenia

This medicinal product is authorised in the Member States of the EEA under the following names:

Name of the Member State	Name of the medicinal product
Austria	Solifenacin HCS
France	Solifenacine HCS
Ireland	Solifenacin TAD
Belgium, Slovakia, Iceland, Norway, Denmark, Finland, Sweden	Solifenacin Krka
Germany	Solifemin
Spain, Croatia, Hungary, Poland	Asolfena
Netherlands	Solifenacinesuccinaat Krka
United Kingdom	Solifenacin succinate

This leaflet was last revised in 11/2020

TAD Pharma
MEMBER OF KRKA GROUP
XXXXXX